Hospira is now officially a part of Pfizer and today marks the first day operating as a combined business. The One 2 One parenteral contract development and manufacturing business will continue its operation alongside Pfizer’s existing contract manufacturing business, Pfizer CentreSource.

The global market value for both generic sterile injectables and biosimilars is expected to grow, estimated to be $70 billion and $20 billion in 2020, respectively. The acquisition expands Pfizer’s portfolio of sterile injectable pharmaceuticals with Hospira’s generic sterile injectables product line, including acute care and oncology injectables, with a number of differentiated presentations. Pfizer’s branded sterile injectables include anti-infectives, anti-inflammatories and cytotoxics.
 
The combined contract manufacturing organization brings together the best of Pfizer and Hospira capabilities to provide a wider array of services and manufacturing technology to clients. One 2 One will continue to operate a commercial office in Lake Forest, IL and plant locations in McPherson, KS; Rocky Mount, NC; Liscate, Italy; Mulgrave, Australia; Chennai, India and Zagreb, Croatia.